Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation



Status:Completed
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 49
Updated:2/17/2019
Start Date:April 2011
End Date:February 2013

Use our guide to learn which trials are right for you!

Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects

The purpose of this study to investigate the effect of sulforaphane from macerated broccoli
sprouts in humans and to evaluate less invasive methods of assessing potential
anti-inflammatory drugs in CF.

The hypothesis to be tested is that sulforaphane consumed from macerated broccoli sprouts
will activate Nrf2, reduce oxidative metabolites and reduce neutrophils in the oral mucosa
after 5 days of therapy in healthy volunteers and CF subjects.

The study requires 6 brief outpatient visits over 8 days. Study procedures include medical
history, height, weight, vital signs, blood and urine collection, nasal curettage, saline
mouthwash, and ingestion of broccoli sprouts (100 gm of 3 to 5 day old raw broccoli sprouts
once daily for 5 consecutive days).

Inclusion Criteria:

- Healthy volunteers and patients with cystic fibrosis ≥ 18 < 50 years of age

- Healthy volunteers must be in general good health as determined by a medical history

- CF subjects must have a documented diagnosis of CF (positive sweat chloride ≥ 60
mEq/liter, by pilocarpine iontophoresis) and/or a genotype with two identifiable
mutations consistent with CF accompanied by one or more clinical features with the CF)
phenotype

- CF subjects must have a baseline FEV1 percent predicted > 50% (in the last year,
obtained from medical record)

- CF subjects must be clinically stable: free of any acute illness for > 14 days CF
subjects must not have been prescribed any new systemic antibiotics for the 14 days
prior to enrollment

- Ability to provide written informed consent

- Ability to adhere to the protocol

Exclusion Criteria:

- Use of NSAIDS (e.g., ibuprofen) or corticosteroids including inhaled steroids for the
4 weeks prior to enrollment

- Active gingival disease (active tooth or gum disease)

- History of nephrolithiasis or cholelithiasis

- Allergy to broccoli

- Any chronic condition that compromises the participant as determined by medical
history

- Pregnancy

- Inability to tolerate the study procedures

- CF subjects: Infected with B. cepacia
We found this trial at
1
site
11100 Euclid Avenue
Cleveland, Ohio 44106
(216) 844-1000
Rainbow Babies and Children's Hospital UH Rainbow Babies & Children’s Hospital is a 244-bed, full-service...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials